amg 108 + methotrexate

**AMG 108 + methotrexate** is a combination therapy investigated for the treatment of **rheumatoid arthritis**. AMG 108 is a fully human IgG2 monoclonal antibody that selectively binds and inhibits the human **interleukin-1 receptor type 1**, thereby blocking the activity of interleukin-1α and interleukin-1β, pro-inflammatory cytokines implicated in the pathogenesis of rheumatoid arthritis[1][2][3]. Methotrexate is a conventional disease-modifying antirheumatic drug (DMARD), acting as a folate antagonist. In clinical trials, AMG 108 was administered subcutaneously (50, 125, or 250 mg every 4 weeks) to RA patients stabilized on methotrexate (15–25 mg/week)[1][3]. The combination demonstrated statistically significant improvements in ACR20 response rates at the highest AMG 108 dose versus methotrexate alone, but overall clinical benefit was modest and dose-dependent[1][3].